Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Silo Pharma, Inc. (SILO)

Silo Pharma buys software and IP from Parkview Consulting for 165,000 shares

Neutral Impact 3 of 5 m&a Written later

Silo Pharma entered into an asset purchase agreement on August 18, 2026, to acquire software, technology, domain names and related intellectual property from Parkview Consulting LLC, paying with 165,000 newly issued common shares. The seller's sole member, Corwin Yu, currently serves as lead strategic advisor on the company's Cryptocurrency Advisory Board, a relationship the filing discloses. The shares are locked up for up to 12 months, and the seller gives indemnification protections.

Key points

  • Consideration: 165,000 shares of common stock, par value $0.0001 per share, issued to Parkview Consulting LLC
  • Lock-up runs until the earliest of 12 months, a Change in Control, or company written consent
  • Seller is owned by Corwin Yu, who is lead strategic advisor on the Cryptocurrency Advisory Board
  • Shares issued under Section 4(a)(2) of the Securities Act of 1933; agreement filed as Exhibit 10.1 with schedules omitted

The filing

CompanySilo Pharma, Inc. (SILO)
Form8-K, current report
Filed with the SECAug 19, 2026, 5:17 PM ET
Accession number0001213900-26-091783

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 19, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.